NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Hansa Biopharma AB (publ) (ST: HNSA)

 
HNSA Technical Analysis
2
As on 25th Apr 2025 HNSA STOCK Price closed @ 28.36 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 36.23 & Buy for SHORT-TERM with Stoploss of 27.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

HNSASTOCK Price

Open 24.00 Change Price %
High 28.38 1 Day 4.68 19.76
Low 23.94 1 Week 6.86 31.91
Close 28.36 1 Month 5.58 24.50
Volume 920211 1 Year 2.66 10.35
52 Week High 55.20 | 52 Week Low 21.12
 
ST Sweden Most Active Stocks
FING-B 0.02 100.00%
HDW-B 0.00 %
WYLD 0.05 0.00%
SBB-B 3.91 1.30%
LUNE 21.97 6.65%
QUIA 0.01 0.00%
QLINEA 0.04 0.00%
POLY 0.04 0.00%
ENERS 0.00 %
EURA 0.01 0.00%
 
ST Sweden Top Gainers Stocks
KOPY 0.10 150.00%
FING-B 0.02 100.00%
SPIFF 0.04 33.33%
LIDDS 0.04 33.33%
NJOB 3.76 28.77%
XINT 0.42 27.27%
ANOT 0.06 20.00%
HNSA 28.36 19.76%
JLT 2.32 16.00%
EFFH 3.06 15.04%
 
ST Sweden Top Losers Stocks
ZICC 0.25 -34.21%
AUR 0.82 -31.67%
AUR 0.82 -31.67%
ALLR 1.55 -26.54%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
ASAP 0.03 -25.00%
GIAB 0.10 -23.08%
BOOZT 80.20 -18.33%
BOOZT 80.20 -18.33%
 
 
HNSA
Daily Charts
HNSA
Intraday Charts
Whats New @
Bazaartrend
HNSA
Free Analysis
 
HNSA Important Levels Intraday
RESISTANCE36.92
RESISTANCE34.17
RESISTANCE32.48
RESISTANCE30.78
SUPPORT25.94
SUPPORT24.24
SUPPORT22.55
SUPPORT19.80
 
HNSA Forecast April 2025
4th UP Forecast57
3rd UP Forecast47.81
2nd UP Forecast42.14
1st UP Forecast36.46
1st DOWN Forecast20.26
2nd DOWN Forecast14.58
3rd DOWN Forecast8.91
4th DOWN Forecast-0.28
 
HNSA Weekly Forecast
4th UP Forecast34.64
3rd UP Forecast32.63
2nd UP Forecast31.38
1st UP Forecast30.14
1st DOWN Forecast26.58
2nd DOWN Forecast25.34
3rd DOWN Forecast24.09
4th DOWN Forecast22.08
 
HNSA Forecast2025
4th UP Forecast101.05
3rd UP Forecast77.74
2nd UP Forecast63.33
1st UP Forecast48.92
1st DOWN Forecast7.8
2nd DOWN Forecast-6.61
3rd DOWN Forecast-21.02
4th DOWN Forecast-44.33
 
 
HNSA Other Details
Segment EQ
Market Capital 4637679616.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
HNSA Address
HNSA
 
HNSA Latest News
 
Your Comments and Response on Hansa Biopharma AB (publ)
 
HNSA Business Profile
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an IgG-degrading enzyme of Streptococcus pyogenes (IdeS), an antibody cleaving enzyme that is in Phase II for enabling kidney transplantations in sensitized patients, as well as for anti-GBM antibody disease and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), a cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: Scheelevägen 22, Lund, Sweden, 222 63
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service